Skip to main content
. 2021 Mar 8;12:630773. doi: 10.3389/fimmu.2021.630773

Figure 2.

Figure 2

Mutational landscape, clinical information of BLCA patients and the characteristics of the NCOR1 mutations in patients. (A) The top 20 frequently mutated genes in BLCA in the Samstein cohort (ICI-treated). The genes were ranked by the mutation frequency in BLCA patients. The asterisks indicate a significant difference between NCOR1-MT and NCOR1-WT. The mutation rates, sex, drug type, and sample type were evaluated using Fisher’s exact test. The TMB and MSI scores were evaluated using the Mann–Whitney U test. (B) The top 20 frequently mutated genes in BLCA in the TCGA-BLCA cohort. The genes were ranked by the mutation frequency in BLCA patients. The mutation rates, clinical stage, race, sex and ethnicity were evaluated using Fisher’s exact test. TMB, NAL and age were evaluated using the Mann–Whitney U test. (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). BLCA, Bladder urothelial carcinoma; NCOR1, nuclear receptor corepressor 1; TMB, tumor mutation burden; NAL, neoantigen load; MT, mutant; WT, wild-type; MSI, microsatellite instability.